CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

durvalumab

Last Updated: December 23, 2020
Result type: Reports
Project Number: PC0234-000
Product Line: Reimbursement Review

Generic Name: durvalumab

Brand Name: Imfinzi

Manufacturer: AstraZeneca Canada Inc.

Therapeutic Area: Extensive-stage small cell lung cancer

Indications: IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

Manufacturer Requested Reimbursement Criteria1: As per Health Canada indication: in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

Submission Type: Initial

Tumour Type: Lung

NOC Status at Filing: Post NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule1: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Submit Feedback

Key Milestones2

Call for patient/clinician input open November 03, 2020
Call for patient/clinician input closed December 24, 2020
Clarification:

- Patient input submission received from Lung Cancer Canada and Lung Health Foundation

Submission received December 01, 2020
Submission accepted December 15, 2020
Review initiated December 16, 2020
Draft CADTH review report(s) provided to sponsor for comment March 22, 2021
Deadline for sponsors comments March 31, 2021
CADTH responses on draft review report(s) provided to sponsor May 03, 2021
Expert committee meeting (initial) May 14, 2021
Draft recommendation issued to sponsor May 31, 2021
Draft recommendation posted for stakeholder feedback -